Merck to Acquire Armata Pharmaceuticals for $1.7B
Ticker: ARMP · Form: 8-K · Filed: Apr 2, 2025 · CIK: 921114
| Field | Detail |
|---|---|
| Company | Armata Pharmaceuticals, INC. (ARMP) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, merger, pharmaceuticals, biotech
Related Tickers: MRK
TL;DR
Merck buying Armata for $1.7B - big pharma swallows biotech!
AI Summary
Armata Pharmaceuticals, Inc. announced on April 2, 2025, that it has entered into a definitive agreement to be acquired by Merck & Co., Inc. for approximately $1.7 billion. The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by Merck, a major pharmaceutical company, could significantly impact Armata's pipeline and the development of its bacteriophage therapies.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a level of uncertainty until completion.
Key Numbers
- $1.7B — Acquisition Value (The total amount Merck is paying to acquire Armata Pharmaceuticals.)
Key Players & Entities
- Armata Pharmaceuticals, Inc. (company) — Company filing the report and being acquired
- Merck & Co., Inc. (company) — Acquiring company
- $1.7 billion (dollar_amount) — Acquisition price
- April 2, 2025 (date) — Date of the report and announcement
- third quarter of 2025 (date) — Expected closing period for the acquisition
FAQ
What is the primary reason for Merck's acquisition of Armata Pharmaceuticals?
While not explicitly stated in this 8-K, the acquisition likely stems from Merck's interest in Armata's bacteriophage technology and pipeline for potential new therapies.
What is the expected timeline for the completion of the acquisition?
The acquisition is expected to close in the third quarter of 2025.
Are there any specific conditions that must be met for the acquisition to be finalized?
Yes, the transaction is subject to customary closing conditions.
What was Armata Pharmaceuticals' former company name?
Armata Pharmaceuticals, Inc. was formerly known as AmpliPhi Biosciences Corp, with a prior name change from TARGETED GENETICS CORP /WA/.
What is Armata Pharmaceuticals' primary business sector?
Armata Pharmaceuticals, Inc. operates in the Biological Products (No Diagnostic Substances) sector, SIC code 2836.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 2, 2025 regarding Armata Pharmaceuticals, Inc. (ARMP).